Saxena AR, Lyle SA, Khavandi K, Qiu R, et al. A phase 2a, randomized, double-blind, placebo-controlled, 3-arm, parallel-group study to assess the efficacy, safety, tolerability, and pharmacodynamics of PF-06835919 in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Diabetes Obes Metab 2022 Dec 14. doi: 10.1111/dom.14946.
PMID: 36515213